Former AngioDynamics CEO Takes Helm at Delcath Systems

Eamonn Hobbs has been named president and CEO of Delcath Systems Inc., a New York, N.Y.,-based medical device firm that focuses on cancer treatments, according to the company.

Hobbs previously worked for AngioDynamics in Queensbury, N.Y., a medical company he co-founded that focuses on oncology, radiology and vascular devices. He replaces Richard Taney, who will remain with the company on its board of directors.

“Eamonn is a proven leader with extensive experience in all aspects of medical device commercialization and the entire Board feels that he is the best person to lead our Company through the next phase of our development,” said Dr. Harold Koplewicz, chairman of Delcath’s board of directors.

Hobbs stepped down from his role as president and CEO at AngioDynamics in March. He remained vice chairman until May 8, when he resigned and left the company.

Delcath Systems is testing a proprietary, patented drug delivery system for the treatment of liver cancers. The company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan.